Effectiveness Study Comparing Treatment With Drug(s) or Adjunctive VNS Therapy for Pharmacoresistant Partial Seizures

This study has been terminated.
Sponsor:
Information provided by:
Cyberonics, Inc.
ClinicalTrials.gov Identifier:
NCT00215215
First received: September 16, 2005
Last updated: February 20, 2006
Last verified: February 2006
  Purpose

To compare outcomes over 12 months of treatment with antiepileptic drugs (AEDs) alone or vagus nerve stimulation (VNS) therapy plus AEDs in patients who have partial seizures refractory to at least two, but not more than five, AEDs.


Condition Intervention Phase
Epilepsies, Partial
Device: Vagus Nerve Stimulation Therapy
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Post Marketing Study; Randomized, Parallel-Group Comparison of Treatment With Pharmacotherapy or Adjunctive Vagus Nerve Stimulation Therapy for Pharmacoresistant Partial Seizures: A Large Simple Effectiveness Trial

Resource links provided by NLM:


Further study details as provided by Cyberonics, Inc.:

Primary Outcome Measures:
  • *Quality of Life in Epilepsy Questionnaire (QOLIE)
  • at baseline, Week 26 and Week 52.
  • *Patients will be asked to keep a daily record of their seizures in a seizure diary supplied by the investigational sites.

Secondary Outcome Measures:
  • The QOLIE at baseline, Week 26 and Week 52.
  • *Percentage Change in Seizure-Related Disability Assessment Scale (SERDAS)at baseline and Week 52 for each patient.
  • *Percentage Change in Hospital Anxiety and Depression Scale (HAD)at baseline and Week 52 for each patient.
  • *Over the course of the study, AED medications will be assessed.
  • *Patient Satisfaction Survey will be performed at Week 52.

Estimated Enrollment: 360
Study Start Date: February 2005
Estimated Study Completion Date: November 2007
Detailed Description:

Published data suggest that patients who continue to experience seizures after trials of two or three AEDs are unlikely to become seizure-free with further attempts at pharmacotherapy. Such patients may experience poor quality of life and functional outcomes from continuing seizures and the adverse effects associated with further attempts at pharmacotherapy. VNS is a non-pharmacologic treatment for epilepsy with well-established effectiveness as an adjunctive treatment (to AEDs) for partial seizures refractory to AEDs, but there are no randomized clinical trials comparing the effectiveness of adjunctive VNS therapy with further pharmacotherapy alone in such patients.

  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient has a diagnosis of partial seizures with onset before age 50, and the patient’s prior electroencephalography and magnetic resonance imaging studies are consistent with the diagnosis of partial seizures.
  • Patient has at least 4 complex partial seizures, but less than 25 seizures (any type), per month during the 3 months preceding randomization; for the 8 weeks preceding randomization, the seizure frequency should be confirmed from a patient diary.
  • Patient has not had an adequate response to an adequate dosage of -- or was intolerant to -- a minimum of 2 different AEDs.
  • Patient has (in the investigator’s judgment) sufficient impairment from his/her epilepsy and/or epilepsy treatment that the potential benefits/risks of VNS therapy are warranted.
  • Patient must currently be receiving at least one AED, but not more than three AEDs, in a stable dosage regimen for at least one month before randomization.
  • Patient must be 12 years of age or older.
  • Patient must be able to provide reliable seizure counts and to complete the evaluations specified in the study procedures flow chart.
  • Patient must provide written informed consent, or legal guardian must give written permission and the minor provide written assent.

Exclusion Criteria:

  • Patient has a history (lifetime) of having received more than 5 different AEDs.
  • Patient has had a bilateral or left cervical vagotomy.
  • Patient currently uses, or is expected to use during the study, short-wave diathermy, microwave diathermy, or therapeutic ultrasound diathermy.
  • A VNS Therapy System implant would (in the investigator’s judgment) pose an unacceptable surgical or medical risk for the patient.
  • Patient is expected to require full body magnetic resonance imaging during the clinical study.
  • Patient has had a previous VNS Therapy System implant.
  • Patient has a previous neuroimaging study that demonstrates mesial temporal sclerosis, cortical dysplasia, or a suspected brain tumor.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00215215

  Show 23 Study Locations
Sponsors and Collaborators
Cyberonics, Inc.
Investigators
Study Director: Carol C Base, RN, MS Cyberonics, Inc.
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00215215     History of Changes
Other Study ID Numbers: E-20
Study First Received: September 16, 2005
Last Updated: February 20, 2006
Health Authority: United States: Institutional Review Board

Keywords provided by Cyberonics, Inc.:
Vagus Nerve Stimulation Therapy
Epilepsies, Partial
Seizures
Antiepileptic Drugs
Refractory Partial Seizures

Additional relevant MeSH terms:
Epilepsy
Epilepsies, Partial
Seizures
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on August 21, 2014